Anti-Angiogenesis Strategies in Cancer Therapies

Erscheinungsjahr 2016
ISBN: 978-0-12-802576-5
Verlag: Elsevier Science Publishing Co Inc

Buch, Englisch, 210 Seiten, Format (B × H): 228 mm x 154 mm, Gewicht: 348 g

Anti-angiogenesis Strategies in Cancer Therapeutics provides a detailed look at the current status and future directions in the discovery and development of novel anti-angiogenesis strategies in oncology. This book highlights the different mechanisms involved in the modulation of angiogenesis, including inflammation, thrombosis, and microRNA, and shows how nanotechnology can further enhance the potential of existing and new anti-angiogenesis approaches.

Written for industry scientists, researchers, oncologists, hematologists, and professors and students in the field, this comprehensive book covers all aspects of anti-angiogenesis strategies and their differences.

Zielgruppe

Pharmaceutical scientists and researchers in pharmaceutical and biotechnology companies, oncologists, hematologists, graduate and post-graduate students in these areas and academic faculty

Autoren/Hrsg.

Mousa, Shaker A.

Mousa, Shaker

Davis, Paul

Fachgebiete

• Technische Wissenschaften Verfahrenstechnik | Chemieingenieurwesen | Biotechnologie Pharmazeutische Technologie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Pharmazie
• Naturwissenschaften Chemie Chemie Allgemein Pharmazeutische Chemie, Medizinische Chemie

Inhaltsverzeichnis

1. Role of Angiogenesis and lymphogenesis in Cancer (tumor growth, Invasion, metastasis2. Role of Angiogenesis and anti-angiogenesis in hematological malignancies (acute / chronic leukemia, lymphoma, myelodysplastic syndromes, myeloproliferative neoplasms)3. The interface between Thrombosis-Inflammation and Angiogenesis4. Micro RNA and Angiogenesis modulation5. Preclinical discovery and development of different Pharmacological anti-angiogenesis agents6. Differences among different anti-angiogenesis strategies (Mechanisms of actions)7. Naturally Occurring Anti-angiogenesis8. Clinical trials with anti-angiogenesis agents: Approved agents9. Angiogenesis Biomarkers and Impact on personalized management10. Efficacy of Anti-VEGF therapy in cancer11. Nanotechnology in enhancing the utility of anti-angiogenesis agents - Combinations with other anti-cancer agents12. Multi-targeted anti-angiogenesis therapy in cancer13. Combination of anti-angiogenesis and chemotherapeutics14. Nanotechnology in enhancing the utility of anti-angiogenesis agents - Combinations with other anti-cancer agents15. Nano-targeted anti-angiogenesis agents in cancer detection16. Future Directions

Über Autor(innen)

Mousa, Shaker
Dr. Mousa came to Albany College of Pharmacy and Health Sciences in 2002 following a career of more than 17 years as a principal research scientist at DuPont Pharmaceuticals Co. Among Dr. Mousa's professional accomplishments are his contributions to many patents - he holds more than 250 U.S. and international patents - and to the discovery and development of novel anti-platelet, anti-thrombotic therapies, non-invasive myocardial perfusion and thrombus imaging agents. Dr. Mousa serves on the editorial boards and as a reviewer for a number of scientific and medical journals, including Journal of Pharmaceutical Sciences, Frontiers in Molecular Neuroscience, Clinical and Applied Thrombosis/Hemostasis, Applied Microbiology and Biotechnology, and PLoS Computational Biology.

Davis, Paul
Dr. Davis directs a group of scientists who have defined molecular mechanisms for many non-genomic, plasma membrane-initiated actions of thyroid hormone, including actions on plasma membrane ion transporters, intracellular protein trafficking, phosphorylation of nuclear hormone receptors and of p53 and on transcription of specific genes. He has 5 patents issued and 25 US and international applications pending. Dr. Davis is a US Faculty Head in Endocrinology of the Faculty of 1000 Medicine and a member of the Endocrine Society, American Thyroid Association, American Society of Biochemistry and Molecular Biology, American Diabetes Association, American Association for Cancer Research and a Fellow of the American College of Physicians.